Clinical trial · Interventional
Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma
Evaluation of the Value of 18F-fluorodeoxyglucose Positron Emission Tomography (FDG PET) and Brain Perfusion Computed Tomography (CT Perfusion) for Predicting the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Patients With Recurrent Glioblastoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this pilot study, the study evaluators will evaluate the ability of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG PET) and the computed tomography (CT) perfusion scanner, individually and combined, to predict the effectiveness of anti-angiogenic treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT scan | Other | — | UNRESOLVED |
| FDG PET | Other | — | UNRESOLVED |
| Magnetic resonance imaging (MRI) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients with recurrent glioblastoma
- interventionNames
- Other: FDG PET
- Other: CT scan
- Other: Magnetic resonance imaging (MRI)
Primary outcomes (1)
- measure
- Categorization of patients as responders or non-responders to treatment
- timeFrame
- 2 months
- description
- Measured by MRI according to Response Assessment in Neuro-Oncology (RANO) criteria: Complete response/Partial response/stable/progression
Secondary outcomes (14)
- measure
- Metabolic Tumor Volume
- timeFrame
- Day 0
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * The patient has an WHO score ≤ 3 * The patient's estimated life expectancy is more than 3 months. * Patient with histologically proven diagnosis of glioblastoma. * Patient presenting with tumor progression on morphological MRI confirmed by a multidisciplinary committee. * Patient with a unilateral supratentorial target lesion upon inclusion to establish a tumor region of interest (ROI) zone and an equivalent ROI zone in contralateral healthy tissue. * Patient progressing after radiotherapy and at least one line of chemotherapy with TEMODAL * Patient in whom treatment with Bevacizumab monotherapy has been validated by a multidisciplinary committee. Exclusion Criteria: * The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study * The subject refuses to sign the consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Pregnant or breast feeding patients * Hypersensitivity to iodinated contrast media and creatinine clearance less than 60 ml / minute.
References
Publications (0)
Data not yet available